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Improved care for people with dystonia presents a number of challenges. Major gaps in
knowledge exist with regard to how to optimize the diagnostic process, how to leverage
discoveries in pathophysiology into biomarkers, and how to develop an evidence base
for current and novel treatments. These challenges are made greater by the realization
of the wide spectrum of symptoms and difficulties faced by people with dystonia, which
go well-beyond motor symptoms. A network of clinicians, scientists, and patients could
provide resources to facilitate information exchange at different levels, share mutual
experiences, and support each other’s innovative projects. In the past, collaborative
initiatives have been launched, including the American Dystonia Coalition, the European
Cooperation in Science and Technology (COST—which however only existed for a limited
time), and the Dutch DystonieNet project. The European Reference Network on Rare
Neurological Diseases includes dystonia among other rare conditions affecting the central
nervous system in a dedicated stream. Currently, we aim to broaden the scope of
these initiatives to a comprehensive European level by further expanding the DystoniaNet
network, in close collaboration with the ERN-RND. In line with the ERN-RND, the mission
of DystoniaNet Europe is to improve care and quality of life for people with dystonia
by, among other endeavors, facilitating access to specialized care, overcoming the
disparity in education of medical professionals, and serving as a solid platform to foster
international clinical and research collaborations. In this review, both professionals within
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the dystonia field and patients and caregivers representing Dystonia Europe highlight
important unsolved issues and promising new strategies and the role that a European
network can play in activating them.
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INTRODUCTION
Dystonia is a movement disorder characterized by sustained
or intermittent muscle contractions causing abnormal, often
repetitive, movements, postures, or both (1). Besides motor
symptoms, dystonia syndromes also include several non-motor
symptoms, with an independent significant impact on health-
related quality of life (2–8).
Dystonia has remained a rather enigmatic disorder despite
it being the third most common movement disorder after
parkinsonism and tremor and despite its major impact on health.
One key problem, which remains today, is the multiplicity
of causes of dystonia. This has meant that the traditional
approach of looking for a unified pathophysiological model for
a disorder, from which one can develop diagnostic biomarkers
and treatments, has been difficult to apply. The possibility
that pathophysiological and treatment efficacy studies are
contaminated by inclusion of people with dystonia of differing
etiologies is a real one and is perhaps an important reason why
progress in treatment development has been slow.
Over the past 1–2 decades, gradual progress has been made
in understanding the genetic underpinnings of some forms of
dystonia, allowing the prospect of studying genetically defined
cohorts of patients. In addition, pathophysiological studies
have become more sensitive to the possibility of combining
multiple etiologies of dystonia, alongside advances in identifying
important subgroups of people with dystonia with specific
etiologies, for example, functional dystonia. The wide spectrum
of symptoms in dystonia has also been recognized, including its
impact on mental health and cognitive and sensory processing.
Treatment advances have been made, particularly in the
successful use of deep brain stimulation (DBS) for certain types
of dystonia, with intracranial recordings performed during these
surgeries providing a novel source of pathophysiological data.
However, many gaps in knowledge remain, and efforts
have been made in recent years to build networks that foster
international research collaboration. One recent EU-focused
infrastructural initiative is the European Reference Network
(ERN) for Rare Neurological Diseases (RND), born with the aim
to improve quality of life for RND patients and to facilitate the
exchange of knowledge between healthcare professionals across
borders (9). A patient can be virtually presented to a specialist in
another country, with the aim to provide the best medical care
without the need to travel. Moreover, it facilitates the collection
of patient data, which is important for research purposes. The
ERN-RND will interconnect tightly with DystoniaNet Europe as
regards goals, PIs, and activities.
Specifically for dystonia, a research network was formed
in 2011 by the European Dystonia Cooperation in Science
and Technology (COST) Action. This action was aimed at
promoting genetic studies, stimulating the development of
experimental animal models, standardizing and harmonizing
patient care, strengthening the scientific or medical expertise of
young researchers and doctors through international exchanges
between European research laboratories and expert centers,
and educating the public and professionals about the disorder.
The original workgroup included applicants from 18 European
countries but later increased to encompass 24 European
countries. There was also collaboration with the American
Dystonia Coalition. Moreover, an important partner was
Dystonia Europe, which is an umbrella organization for 22
national dystonia patient associations in 18 European countries,
aiming at improving quality of life for people living with
dystonia by focusing on the following: raise awareness, spread
information, promote education and research, support lobbying
and advocacy, and add value to the work of member associations.
Another collaborative multidisciplinary network was
initiated in The Netherlands. In 2010, the Movement Disorders
workgroup of the Dutch Neurological Society brought together
several movement disorders specialists and physiotherapists to
initiate DystonieNet. The main goal of this national network
was to optimize cervical dystonia (CD) treatment by facilitating
collaboration between experts, educating more healthcare
providers, and promoting research. Another aim was to facilitate
the patients’ access to dystonia experts to quicken and improve
diagnosis and treatment. In this context, a Dutch website
(dystonia.net) was developed that serves as a platform for
healthcare professionals. This website gives information on
regional, national, and international meetings, focused skills
workshops, and ongoing research studies on dystonia. A special
feature on the website is the “Care Searcher” tool that lists all
botulinum toxin units, movement disorder neurologists, or
physical therapists specialized in dystonia, who can then be
located by patients and clinicians by typing their zip code area. In
addition, a newsletter is issued several times a year to spread the
most recent news in the field of dystonia, and a special mobile
phone application has been developed that provides information
about the national guidelines for botulinum toxin treatment, as a
handy tool in the outpatient clinic.
From the experience of the COST Network and the Dutch
DystonieNet, the network was expanded to become DystoniaNet
Europe. The aim of this European project is to expand the
scope of the Dutch DystonieNet project to a European level.
In the initial phase, Ireland and Slovakia joined the website
project, and currently, more countries are in the process of
joining. All the authors of this paper (see Authors/collaborative
working group) represent countries, invited to be part of
DystoniaNet Europe. Authors were selected based on their
previous participation in European initiatives about Dystonia,
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but the participation in the Network is surely not exclusive. The
topics of the paper were assigned to different members of the
writing committee. A draft of the paper was shared with all
the authors in the Authors/collaborative working group, who
contributed important intellectual content.
The above-mentioned projects are major steps to provide
answers to important knowledge gaps. In this paper, we will
identify some of the unmet needs, not only both from the
perspective of health professionals and researchers but also
of the patients and caregivers across Europe. Patients’ quotes,
collected by DystoniaEurope, highlight the unmet needs shared
by professionals and patients. We will also try to define the
role that a European network such as DystoniaNet can have in
facilitating the solution to these problems, as summarized in
Table 1.
DIAGNOSTIC PROCESS
Improving Dystonia Awareness Among
Patients and Clinicians
Currently, the diagnosis of dystonia is merely based on physical
examination and recognition of patterns by an experienced
clinician. This can be a diagnostic challenge due to a wide
range of dystonia phenotypes and etiologies as well as dystonia
mimics (such as functional dystonia). Dystonia can have different
characteristics and can be the only symptom but also present as
part of a mixed neurological and even systemic disorder (10). The
etiological and clinical classification can be particularly difficult
in childhood onset dystonias (11).
Due to the rarity of the disorder and the complexity of the
presentation, there is often a significant delay in diagnosis. In
CD, which is the most prevalent form of dystonia with well-
defined clinical symptoms, the mean time from symptom onset
to diagnosis varied in several studies from 3.7 (12) to 6.8 years
(range, 0–53 years) (13) (for a patient’s experience, see Box 1).
Similar diagnostic delays were observed for other adult-onset
focal and segmental dystonias, where in almost half of the cases,
it took more than a year to reach the diagnosis (14).
Improvement of dystonia awareness and knowledge can be
expected to enable patients to be referred more quickly to
an experienced clinician and to obtain a correct diagnosis
and addressing their symptoms more rapidly (for a patient’s
experience, see Box 2). The introduction of a nationwide Care
Searcher tool could then help gain access to a more advanced
diagnosis by amovement disorder specialist (including syndrome
characterization and genetic profile) and to adequate treatment,
including identifying patients who are candidates for more
advanced treatments such as surgical therapies, including DBS.
Besides that, in some countries (e.g., France), government
actions have labeled Centers of Excellence for Rare Diseases,
whose mission is to identify places of diagnosis and therapeutic
expertise, as close as possible to patients and to ensure regional
and national networks.
Education of medical professionals is one of the most
important steps to achieve these goals. Here, a European network
can play a role by the organization of training for general
practitioners, general neurologists, and physical therapists. There
is a need for a more structural practical education around
dystonia diagnosis and treatment (for example, botulinum toxin
workshops): these could be implemented also in the context
of movement disorders curricula or fellowship programs for
residents and young fellows, which are however lacking in some
countries (15). In the COST initiative, three “dystonia schools”
(Bol, Croatia; Groningen, the Netherlands; London, UK) were
organized for young neurologists and scientists. In addition,
awareness in the general population may be increased by means
of media campaigns at a European level, involving national
patient associations through Dystonia Europe. DystoniaNet, in
close collaboration with the ERN-RND, can play a significant role
in this.
An Algorithm for the Diagnosis of Dystonia
Dystonia can be classified based on clinical characteristics
(axis I, including age at onset, body distribution, temporal
pattern, and associated features) and etiology (axis II) (1).
Clinical characteristics form the basis for the etiological clinical
suspicion and thereby give an indication of which supplementary
laboratory tests or imaging should be performed.
The major developments in genetic testing, allowing us to
analyze many genes in a relatively short time, make the case for
a renewed diagnostic strategy: recently, a diagnostic algorithm
has been proposed for dystonia occurring in children and
adolescents (16). Similarly, we could envisage a diagnostic model
for adults (see below). This should consider the availability of
the diagnostic modalities in different countries and be open
to continuous updates as knowledge increases and techniques
become readily available and affordable. When a specific
investigation (like genetic testing) is not available in one country,
international collaboration may provide the solution to complete
the diagnostic process. When all patients have undergone the
same diagnostic process, larger groups of well-characterized
rare dystonia subtypes can be collected, which would increase
the statistical power of research at a pathophysiological and
treatment level.
Genetics
In 1997, the TorsinA (TOR1A) gene was the first to be identified
as the major cause for young-onset (primary) generalized
dystonia (17). However, monogenic causes of dystonia can only
be found in 1–2% of the patients in an average dystonia clinic (18,
19). The other subgroup of dystonia with a genetic background
includes the hereditary disorders in which dystonia is part of the
symptom spectrum. This list contains isolated, combined, and
complex dystonias. Importantly, some of the hereditary forms
include treatable (metabolic) diseases (16).
In clinical practice, the possibility of testing for a genetic
background of dystonia has evolved rapidly. With the
development of next generation sequencing (NGS), it has
become possible to analyze thousands of genes simultaneously.
One of the NGS techniques involves targeted gene panel analysis,
in which a specific set of preselected genes is tested. Compared
with other techniques like whole-genome and whole-exome
sequencing, the costs of a gene panel analysis are lower, and there
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TABLE 1 | Goals DystoniaNet Europe.
Priorities of action of DystoniaNet Europe Highlights
Diagnostic process
Improving dystonia awareness among patients
and clinicians
• Organization of trainings for GPs, neurologists, physical therapists, with focus on diagnosis and
treatment (for example botulinum toxin treatment).
Algorithm for diagnosis of dystonia • Development of a diagnostic model for adult onset dystonia
Genetics • Sharing of technical knowledge across gene banks
• Pooling of data across existing genetic databases
• Development of a European biobank
Neurophysiological diagnostic biomarkers
dystonia
• Development of neurophysiological markers to discriminate dystonia from other movement disorders
and to differentiate idiopathic, acquired, and functional dystonia
• Gain knowledge of dysfunctional brain networks
• Development of biomarkers for the effectiveness of DBS
Imaging biomarkers • Gain knowledge about pathophysiological mechanisms
• Development of automatic algorithms of image analysis
Endophenotypes • Organization of large prospective studies of patients and relatives to prospectively
study endophenotypes
Treatment
Physical and occupation therapy • Collection of evidence on different training programs and on cost effectiveness
• Development of dystonia specific training programs, with a personalized approach
• Collection of evidence about the effect of physical therapy and occupational therapy on
pathophysiological mechanisms
Botulinum toxin treatment • Collection of more evidence about some treatment aspects (e.g., use of polymyography and ultrasound
in guiding injections)
• Clinical studies aimed at improving the benefit/side effect ratio and reducing the number of non-
responsive patients
• Development of uniform European BoNT treatment guidelines
• Improvement of access to treatment
Deep brain stimulation • Development of an expert network across European countries for clinical consultation, sharing
experiences, and outcomes
• Development of European Dystonia DBS registry/biobank aimed to collect information about DBS
outcomes in rare forms of dystonia and in children, rare side effects, and unexpected responses
• Collection of evidence about biomarkers predictors of outcome
Non-motor symptoms • Development of a non-motor symptom questionnaire for different dystonia subtypes
• Improvement of treatment of non-motor symptoms
• Development of a subjective goal outcome scale
• Development of a multidisciplinary approach
BOX 1 | Patient’s experience.
Dystonia patient: “Today I was diagnosed with dystonia after 18 years of having these awful shakes where everyone thinks I am saying no. I now have a name for it.
It is not essential tremor, it is not in my mind, and it is a very real condition.”
are fewer spurious findings (20). The panel approach results in
a higher percentage of confirmed molecular diagnoses than a
more classical clinical approach based on diagnostic hypotheses.
In addition, the average costs and the time needed to reach an
etiological diagnosis are lower when gene panel analysis is used
compared to single gene analysis (20, 21).
Genetic testing should be considered mainly in young onset
dystonia patients, patients with a positive family history, patients
with paroxysmal dystonia, and patients with other (neurological)
symptoms (18, 20, 21). The benefits of testing include diagnostic
certainty for the individual patient, which then can avoid
further unnecessary investigations, information about the risk
of recurrence in the family (22), and prevention of transmitting
the affected gene to the next generation. This of course comes
together with ethical issues that need to be addressed. Although
rare, a genetic diagnosis may, in some cases, also alter treatment.
Gene panel analysis is likely to play an important role in the
future. However, at this time, it is not uniformly available, and
there are differences in patient selection, counseling, and gene
panel composition across different countries. In addition, the
rapidly expanding genetic findings require a systematic update
of the genes included in the gene panel. A uniform panel across
Europe, with a centralized update system, could have major
benefits. Knowledge could be exchanged across laboratories, and
techniques for coverage and lab protocols can be shared and
optimized. For research purposes, a uniform approach would
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BOX 2 | Patient’s experience.
Dystonia patient: “Much more needs to be done to raise awareness of this disease. General practitioners and nurses need to be educated on it. We get fed up
hearing: “oh it is like Parkinson’s then”.”
make it possible to derive reliable epidemiological data across
countries and to create large cohorts of patients and controls
to test for variants of unknown significance. For this purpose,
following the example of some national databases such as
the German DysTract, bio banking at a European level could
be pursued. Alternatively, a more open and easier sharing of
regional or national gene banks would allow for a continuous
actualization and implementation of clinical and genetic data.
This would form the basis to identify new causative and disease-
modifying genes or risk factors for dystonia and attribute clinical
significance to variants of unknown pathogenicity for genes
already identified. In the future, the discovery of more dystonia-
related genes, and the unraveling of the highly complex network
of cellular pathways, will eventually increase our understanding
of the dystonia pathophysiology and hopefully create new
treatment options (23). Moreover, a European network could




Electrophysiological and sensory perceptual studies have
supported the view of dystonia as a disorder of network
dysfunction involving the basal ganglia, thalamus, cerebellum,
and sensorimotor cortices (24).
Despite major advances that have provided a better
understanding of dystonia pathophysiology by means of
different neurophysiological techniques (25–28), the diagnosis
mainly relies only on clinical features. It would be a major
advantage if (1) neurophysiological testing could reliably
discriminate dystonia from other movement disorders and (2)
could support the etiological diagnosis (idiopathic, genetic,
or functional) (for a patient’s experience, see Box 3). To
date, neurophysiological studies have been inconsistent in
differentiating idiopathic from functional (29, 30) or genetic
dystonia (31). Only recently, a few studies found between-groups
differences using different neurophysiological techniques in
subjects with different etiologies of dystonia (32–35). It has
been possible to distinguish between children with acquired
isolated genetic or idiopathic dystonias using a corticomuscular,
intermuscular, and sensory perturbation paradigm (32). In
small sample size studies in adults, the blink reflex recovery
cycle (33) and the paired associative stimulation protocol (used
to test sensorimotor plasticity) (34, 35) have been effective
in discriminating, respectively, cranial and limb functional
dystonia from idiopathic dystonia. However, sensorimotor
plasticity has been shown to be highly variable across subjects
with different phenotypes of idiopathic dystonia and also
within the same phenotype (36). In addition, although it has
been hypothesized that different phenotypes of dystonia reflect
altered processing at different levels of a dysfunctional brain
network (37), there is only preliminary supporting evidence for
CD (38).
Confirmation by testing homogeneous cohorts of subjects is
needed to define which neural networks may underlie different
dystonic manifestations (tremor, tonic posturing, patterned
movements), localization in different body parts, and associated
non-motor symptoms, such as pain. Finally, as the discriminatory
power at individual level for any of these neurophysiological
paradigms have never been tested, it is crucial to design studies
on large samples to test putative diagnostic biomarkers in
idiopathic dystonia, which may aid the differential diagnosis
primarily with functional dystonia, given the normality of
structural neuroimaging in both conditions and the different
therapeutic pathways.
From a methodological point of view, there are several
technical challenges. One challenge is to investigate whether
different components of the network are involved in
generating the heterogeneous clinical picture of dystonia.
Electrophysiological signals from the cerebellum have
traditionally been viewed as inaccessible to magnetoenc
ephalography (MEG) and electroencephalography (EEG).
However, recent advances have allowed MEG and EEG to detect
cerebellar activity using a high-resolution tessellation model
of the cerebellar cortex constructed from repetitive high-field
(9.4 T) structural MR imaging (39).
Transcranial magnetic stimulation (TMS) has been
used extensively to study motor cortex physiology and
plasticity in dystonia, as well as sensorimotor integration
(25). However, reproducibility of results across studies
has been difficult. Multimodal approaches integrating
different neurophysiological techniques with neuroimaging
are envisaged not only to support the diagnostic
process (i.e., functional and genetic dystonias) but also
to determine predictors of response to treatment, in
particular DBS.
Another possible biomarker for the effectiveness of DBS
in dystonia is intermuscular coherence analysis. In children,
both idiopathic/genetic and acquired dystonia share an
abnormal low-frequency intermuscular coherence, but their
intermuscular coherence patterns respond differently to
a sensory perturbation (32). In adult dystonia patients,
low-frequency and beta band intermuscular coherence
partly correlate with dystonia severity and improvement
after DBS. This finding suggests that intermuscular
coherence can function as a biomarker for DBS efficacy
in dystonia, although confirmation in larger studies
is needed.
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BOX 3 | Patient’s experience.
Dystonia patient: “A test to diagnose dystonia would help to reduce the time to a diagnosis and to increase its certainty.”
Increased low-frequency activity (3–12Hz) in the internal
globus pallidus (GPi) of dystonia patients has also been reported
as a potential biomarker (40) that is coherent with dystonic EMG
discharges and correlates with symptom severity as assessed by
dystonia rating scales in a large cohort of patients with CD (41).
In patients that present predominantly with phasic components,
DBS indeed decreases this pallidal low-frequency activity (42),
and DBS contacts localized close to the highest low-frequency
peak are clinically most effective (41), which could be useful
for parameter selection for DBS or as a feedback signal for
closed-loop stimulation in the future.
These specific neurophysiological tests require expertise and
often need to be performed on expensive machines. This
restricts research on neurophysiological markers to a few
specialized centers. To this end, a European network such as
DystoniaNet together with the ERN-RND could support the
diffusion of a broader knowledge of specific techniques among
neurophysiologists and the pooling of larger cohorts of patients
for neurophysiological studies. Further developments in the
neurophysiological field could aid the diagnostic process and
form a powerful tool for guiding new treatment approaches with
less side effects.
Imaging Biomarkers
Morphological and functional imaging currently offers no
reliable markers that can be used in the differential diagnosis
of dystonic syndromes. Some notable exceptions are dystonia
syndromes caused by neurodegenerative disorders and disorders
associated with focal lesions or with metal accumulation in
the basal ganglia such as neurodegeneration with brain iron
accumulation (NBIA) and Wilson’s disease.
For the other forms of dystonia, limited local changes in gray
matter volume or thickness, subtle changes in the organization
of white matter, and aberrant functional connectivity affecting
large-scale networks can be detected only on a large group
basis. Knowledge in this field is still relatively scattered due
to high phenotype variability. Most imaging studies concern
focal dystonias, and relatively little is known about generalized
dystonic syndromes.
Imaging findings have contributed to the understanding of
dystonia as network disorders (nexopathies, circuitopathies) (43).
The weakness of all imaging studies is the fact that they cannot
distinguish between cause and effect (44). Usual findings include
frequent structural changes and hyper-/hypoactive connections
involved in somatosensory perception and its integration into
motor circuits (45–47). These are mainly the cortico-striato-
pallido-thalamo-cortical pathway and the cerebello-thalamo-
cortical pathway, the dysfunction of which is manifested in
both focal and generalized dystonias (48). The first one, which
involve connections from the basal ganglia and thalamus
to the primary sensorimotor cortex, is hyperactive and less
responsive to regulatory feedback stimuli from the cortex and
subthalamus (44) and thus probably associated with well-known
hyperexcitability of the motor cortex (49). The latter causes
insufficient inhibition of the motor cortex via hypofunctional
connection projecting from the cerebellum through the thalamus
(50). Interestingly, local changes in the SM cortex correspond
to the cortical representation of body segments affected by task
specific dystonias (51–53).
The variability of morphometric findings, functional activity,
and connectivity of the motor network largely depends on
the genotype of dystonia and, to some extent, on the
genotype/phenotype interaction. Basal ganglia volume and
activity differ not only among different mutations (DYT-TOR1A,
DYT-THAP1) (54) but also between DYT-TOR1A patients and
DYT-TOR1A asymptomatic carriers (55). However, there is no
universal imaging picture on which a genetic mutation could
be predicted.
Resting-state functional MRI (fMRI) (as opposed to a task-
based fMRI), has the advantage of not being contaminated
with the executive or sensory component of the voluntary
movement and has shown that the dystonic motor network is
abnormally connected even at rest. In task-specific dystonia,
changes in basal ganglia, primary sensory cortex, and premotor
and parietal cortices have been shown (56, 57). In CD patients,
increased connectivity of the putamen and its connections with
the cortex and other basal ganglia partially normalize after
botulinum toxin injections (44). In addition, CD patients who
can temporarily relieve dystonia using a sensory trick showed
reduced resting connectivity of the SM network and increased
cerebellar connectivity while imagining this trick (58). Thus,
findings in focal dystonia are, to some extent, variable but limited
to sensorimotor circuits, which has also been confirmed by
multimodal studies (51, 59).
Imaging studies in dystonia have already had some practical
consequences both in supporting the differential diagnosis of
dystonia and in predicting DBS effect.
A meta-analysis of the anatomical position of the active
contacts of implanted DBS leads allowed for the construction of
a probabilistic map associated with the clinical benefit of pallidal
DBS. The sweet spot was located at the ventrolateral margin of
the GPi and sub-pallidal white matter (60). The volume of tissue
activates also quantitatively affected the structural and functional
connectivity of the premotor and motor cortices, thalamus,
supplementary motor area (SMA), and cerebellum, proving the
remote effects of pallidal DBS in dystonia patients (61). These
results indicated that imaging could be used for optimal targeting
and even to inform stimulation parameter choice.
Furthermore, great hopes are placed on automatic algorithms
of image analysis based on neural networks and machine
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learning. The automatic classification of resting-state fMRI has
correctly detected patients with spasmodic dysphonia (SD) (62),
CD (63), or alien-hand dystonia in corticobasal syndrome (64)
with sufficient sensitivity and specificity. This approach seems
promising also in the search for potential biomarkers predicting
future clinical effects of DBS. For example, classification using
a support vector machine based on the distribution of cortical
atrophy within the associative, SM, and visuomotor areas resulted
in 88% accuracy in estimating the pallidal DBS outcome in
patients with segmental and generalized dystonia (65). The future
use of these methods therefore seems promising.
Combining different techniques together, such as supervised
machine learning applied to standard diagnostic brain MRI
together with measuring central motor conduction times
(CMCT) with transcranial magnetic stimulation (TMS), or -
evoked potentials (SEPs) together with dystonia severity scales,
can help counsel patients and families of dystonic children
regarding the likely benefit of DBS in acquired dystonias as
well as provide personal predictive and decision-making data
using receiver operating characteristic (ROC) curves (66). This
process applied internationally could rapidly build gene-specific
and acquired disease-specific decision-making tools.
Endophenotypes
Temporal discrimination, the ability to determine two sequential
stimuli as separate in time, is disturbed in a number of basal
ganglia disorders. Abnormal temporal discrimination is not
specific for idiopathic and genetic (67) dystonia but can also
be found in functional dystonia, albeit being produced by a
different mechanism (68). It is, however, a highly sensitive
measure with 97% sensitivity in the most common form of
adult onset focal dystonia: cervical dystonia. It shows age- and
sex-related penetrance in unaffected first-degree relatives, being
found in ∼50% of female first-degree relatives after the age of
40 years, indicating full (100%) penetrance; in male relatives, its
penetrance is∼40% (69).
Accumulating evidence over the last 15 years has indicated
that abnormal temporal discrimination is a mediational
endophenotype in adult-onset dystonia. The features of
mediational endophenotypes are as follows: (a) they are an
expression of a genetic mutation, necessarily present prior to
disease onset; (b) they reflect disease susceptibility and are not
altered by disease expression or severity; and (c) they are more
penetrant than the phenotype (70).Mediational endophenotypes,
found both in CD patients and, importantly, in their unaffected
relatives, may illuminate pathogenetic mechanisms not obvious
from the motor phenotype.
Further support of this endophenotype is that, in unaffected
relatives with abnormal temporal discrimination (compared to
relatives with normal temporal discrimination), it is associated
with increased putaminal volume (71), reduced putaminal
activity (72), and reduced activation in the superior colliculus in
response to a looming stimulus (73).
It is proposed that abnormal temporal discrimination
indicates a disturbance in the system involved in covert
attentional orienting, involving processing of salient
environmental sensory stimuli through the superior colliculus.
The midbrain covert attentional network captures changes in the
environment potentially important for survival, which requires
inspection and action. It is likely that impaired inhibition, caused
by defective GABAergic mechanisms at the level of the synapse,
underlies both abnormal temporal discrimination and dystonia.
It is also likely that non-motor symptoms in dystonia,
like mood disorders and abnormal social cognition, are also
driven by disrupted subcortical mechanisms of covert attention.
Salient environmental stimuli include emotional threats (visual
or auditory) and require emotional threat detection by the
medial amygdala. Social cognition (74) integrates cognitive
processes, such as the ability to follow eye gaze, share attention,
and recognize emotion, to distinguish between self and others’
intentions. There are preliminary studies indicating disordered
basic social cognition in patients with adult onset dystonia (75–
77). It is suggested that abnormal basic social cognition (to
emotional face and voice stimuli) in patients with CD reflects
disrupted subcortical processing in the collicular–amygdala
pathway for threat detection (basic social cognition). This may
be linked to heightened levels of anxiety and depression.
The results from different studies on social cognition in
focal dystonia have been often contradictory; a recent large
study assessing all four major social cognition dimensions found
that participants maintained generally intact social cognitive
abilities (78). The authors did note reduced recognition of facial
expressions of fear; some patients with CD showed defective
empathy. In another study, higher anxiety and depression levels
were associated with better performance on an Facial Affect
Naming task, suggesting that patients with CDmight overactivate
perceptual processing of social stimuli to compensate for baseline
increases in anxiety levels and lowered mood (79). Most of
the, admittedly limited, research shows little evidence of deficits
in complex social cognition in adult onset focal dystonia,
but basic social cognition, including emotion recognition in
facial expressions and prosody, may be impaired; this requires
further investigation.
Given the high penetrance of abnormal temporal
discrimination in unaffected female relatives, it may be
worthwhile to examine the prevalence of mood disorder and
impaired social cognition in this population (in comparison to
female relatives with normal temporal discrimination) and to
follow them up prospectively.
In addition, this purpose can only be achieved by means of




Nowadays, the treatment of dystonia consists of several possible
strategies, depending on the age of the patient, dystonia
subtype, or other specific factors. The effect of treatment can
be monitored by several motor scales, although they frequently
fail to observe small effects. In general, oral medication such
as anticholinergics, physical therapy, botulinum toxin (BoNT)
injections, or surgical treatment including DBS or ablative
procedures can be considered. Here, in cooperation with the
Frontiers in Neurology | www.frontiersin.org 7 June 2021 | Volume 12 | Article 646841
Smit et al. Dystonia Management Within DystoniaNet Europe
ERN-RND, we will focus on the need for European guidelines for
physiotherapy/occupational and BoNT therapy and the unmet
needs for DBS.
Physical and Occupational Therapy
A specific physical therapy (PT) intervention for CD has been
described by JP Bleton (80). It aims to strengthen the non-
dystonic antagonist muscles and to learn or relearn motor skills.
A recent single-blinded randomized controlled trial investigated
the effectiveness of a specialized PT program on disability in CD,
compared to a regular PT program (81). Both groups showed a
significant improvement of motor symptoms after 12 months of
treatment, but no difference between groups was found, as both
programs were effective. However, the specialized therapy group
showed significant improvement in general health perception
and self-perceived improvement over the general therapy group
(for a patient’s experience, see Box 4). Importantly, total health-
related costs were lower in favor of the specialized therapy group.
In the Netherlands, several physical therapists were trained for
this study and continued treating patients with the specialized
therapy after the successful results. Currently, it is crucial to
widely spread the knowledge to physiotherapists across Europe
and to provide them with adequate training. To this end,
international training schools and active professional networks
should be organized to promote exchange of experiences and
the implementation of standardized physiotherapy programs
across Europe.
This could result in an improvement of treatment with a
reduction in motor symptoms and lower costs (for a patient’s
experience, see Box 5). Moreover, considering that many patients
still consult a physical therapist first after the onset of dystonia
symptoms, the delay in diagnosis could be improved.
Recently, a cognitive orientation for occupational therapy
(COOP) approach has been successfully studied in children
and adolescents with acquired and genetic dystonias, who,
after DBS were not achieving their goals (riding a bicycle,
applying mascara, catching and throwing balls, swimming,
feeding, carrying, and pouring drinks) (82). COOP, previously
used in stroke rehabilitation in adults with developmental
coordination disorder, was shown effective in one study focused
on three participant-selected goals. The trained COOP skills were
transferable to two additional untreated goals, and the result was
obtained over 10 1-h sessions compared to hundreds of hours of
“conventional therapy practice” sessions in the past. Extension of
this technique with multiple therapists has been studied, and the
application of COOP to children and young people without DBS
is now required.
The search for the most effective physical treatment program
for dystonia patients is far from over. There is a need for different
approaches for different kinds of dystonias, in both children
and adults, taking into consideration the affected body region,
the symptoms severity, the presence of comorbidities, and age,
social life, and skills of the patients. Ideally, every patient should
receive a personalized approach (such as COOP), based on the
experience of the physiotherapist and the patient preferences.
To this end, new studies should be designed with sufficiently
large populations, which would require multicenter efforts.
Future research should also focus on the effect of PT and OT
on the pathophysiological mechanisms of dystonia and how this
relates to the maladaptive neuroplastic changes (83). This would
improve the understanding of pathophysiological mechanisms
and possibly improve therapeutic strategies. Finally, a broad
training program for physiotherapists should ideally rely not only
on solid evidence of efficacy but also on data about feasibility and
cost effectiveness: such studies are currently scarce.
Botulinum Toxin Injections
BoNT injections are the most important treatment choice for
focal dystonias but can also be used in segmental or generalized
dystonias to relieve symptoms. Extensive research resulted in
class I evidence to support efficacy and safety of several BoNT
formulations (83). Up to 70–85% of CD patients report a
significant benefit on the motor symptoms but also on pain and
quality of life (83).
However, there are still uncertainties, such as the optimal
starting dose, the interval between injections, or the need for
single or multipoint injections in dystonic muscles. Especially
after long-time treatment, neutralizing antibodies can develop,
with a negative effect on BoNT efficacy (84, 85). In addition,
dystonia syndromes with tremor may require a different
approach, which needs further investigation. The use of
polymyography seems to be effective in guiding injections and
improving patient satisfaction but needs confirmation in larger
studies. In addition, the use of ultrasound to target muscles and
reduce the episodes of dysphagia seems to be a promising option
to improve botulinum toxin treatment (83, 86).
Uniform European BoNT treatment guidelines could improve
treatment for patients and enable further research toward
improving the benefit/side effect ratio of BoNT treatment
and reducing the number of primary and secondary non-
responsive patients. A standardized working definition of non-
responsiveness should be developed, and dose finding and
comparative studies across different BoNT toxins should be
performed. In addition, the additional value of polymyography
and ultrasound should be examined.
Another important need is to improve access to treatment
uniformly. It is currently unclear how many patients who
are candidates for treatment are not receiving it. Factors that
explain under-referral should be investigated and addressed,
including lack of knowledge among treating physicians, costs,
and scarce availability of BoNT centers in some areas (15).
The development of a multidisciplinary consultation were
the patient visit the movement disorder specialist, directly
followed by polymyography and treatment with BoNT, can also
significantly improve the diagnostic and treatment process for the
individual patient.
Deep Brain Stimulation
Dystonic symptoms can severely impair the patients quality of
life, while the response of dystonia to oral medical treatment
may be disappointing (87). DBS has been applied for different
forms of dystonia since the late 1990s (88–90). Satisfactory results
can be safely achieved in most patients—including very young
children (91) who go through rigorous selection to identify and
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BOX 4 | Patient’s experience.
Dystonia patient: “I have had cervical dystonia for at least 2 years and was treated with botulinum toxin with little effect. When I finally came to a physical therapist
specialized in dystonia, it was the turning point. From her I got tools such as special exercises and advice on how to manage my dystonia. It was nice to start to feel
some control again. My family has also witnessed how much happier I was after I started seeing the physical therapist.”
BOX 5 | Patient’s experience.
Dystonia patient: “I have been suffering from cervical dystonia for 14 years. I am receiving botulinum toxin treatment. A few years ago my neurologist referred me to
physiotherapy at a local hospital in the town where I live. On the first appointment, it turned out that my physiotherapist had never heard of dystonia, but said she
would try to help me. She was stretching my muscles for an hour. I did not want to risk worsening my condition and did not continue this therapy. As far as I know
there is a lack of physiotherapists in my country who are familiar with dystonia and can help patients with this condition.”
characterize specific types of dystonia known to benefit most
from DBS (92–94) (for a patient’s experience, see Box 6).
DBS is a complex therapy that requires a team of
highly specialized allied health professionals, neurologists and
neurosurgeons, specific technical equipment, and expensive
implantable materials. DBS management requires an intensive
follow-up after surgery. This therapy may present with
complications and rare and poorly understood side effects that
need to be recognized and handled. In addition, the DBS field
advances quickly, as new technological tools arrive on the market
(95). The complexity of DBS treatment increases when different
types of dystonia are concerned due to the availability of different
targets (GPi, different thalamic targets, subthalamic nucleus), the
wide range of possibilities with advanced stimulation options,
and the variable response that can be observed. It is also
worth mentioning that neurosurgical treatment of dystonia
is not restricted to DBS alone but includes other options
such as stereotactic lesioning, MRgFUS, or selective peripheral
neurosurgery, which can be combined or may be proposed
as an alternative or even as a rescue treatment in selected
cases (96–100).
Unfortunately, not all patients experience the optimal
benefit from DBS, and the response of different forms
of dystonia, some of which are very rare, still needs to
be adequately investigated. Finally, when severe forms of
generalized dystonia needing surgical treatment concern
children, the range of skills and expertise required becomes even
wider (101, 102).
Regarding these considerations, it is evident that DBS for
dystonia can only be offered in selected specialized centers. The
geographical distribution of such centers is not uniform across
Europe: some countries have no center at all (15), and some DBS
centers do not treat dystonia patients or have a low volume of
surgeries due to the lack of resources or qualified personnel. As a
result, patients in some areas currently do not have access to this
effective treatment (103) (for a patient’s experience, see Box 7).
Moreover, while DBS centers with significant experience in
this field can encounter difficulties in patient selection and
postoperative management, such problems apply even more so
to centers with less experience or smaller annual volume.
An expert network across European countries, gathering
regularly in (virtual) meetings, could provide the needed
infrastructure for clinical consultation in relation to challenging
cases, exchange of experiences with the prevention and
management of complications, and sharing of outcomes for
the rarest forms of dystonia undergoing surgery. The virtual
consultation infrastructure of ERN-RND as well as bilateral
agreements between centers of different countries within the
network could facilitate referral of patients to centers with
specific expertise for treatment.
Such an initiative could have an immediate impact on daily
practice, but it could also form the basis for the institution of
a European Dystonia DBS registry, as it has been implemented
already in some countries at a national level for special forms
of dystonia in children (104). The registry could serve to collect
information about DBS outcomes in rare forms of dystonia and
in children, rare side effects, and unexpected responses.
At a subsequent stage, it could be supplemented with
infrastructures for biobanking. Indeed, although a growing
amount of data suggest that some patient characteristics may
inform patient selection for surgery (105–108), at the moment,
there are only tentative clinical, neuroradiological, genetic,
or neurophysiological elements that could predict individual
surgery outcome [as described above (66)]. Such much-needed
biomarkers need to be rolled out across a wider population and
pooled diagnostic subgroups, and this requires a collective effort,
where different centers would not only contribute clinical data
but also share infrastructures and expertise in the different fields.
Non-motor Symptoms
Recently, the importance of non-motor symptoms (NMS)
associated to dystonia has been brought to light. The lifetime
prevalence of psychiatric disorders can reach up to 91.4% in
CD patients and mainly consists of depressive symptoms and
anxiety disorders (3, 109). Besides psychiatric disturbances, other
NMS such as fatigue, sleep disorders, and pain are also highly
prevalent (4).
Recognition and correct evaluation of the NMS associated
with dystonia is of paramount importance for the choice of
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BOX 6 | Patient’s experience.
Dystonia patient: “Recently I have had deep brain stimulation and right now I can look at you straight, so I feel amazing! My life … it is like being reborn … it is crazy
… I can wake up, I can go to work, I can drive my car, I can do shopping, I can go around, I can go to a bar, I can talk to people. Last night I was in the bar here and
I talked to everybody, whereas before that never happened. My confidence is back.”
BOX 7 | Patient’s experience.
Dystonia patient: “My doctor had even no idea that you can get deep brain stimulation for dystonia or whether that was a good option for me or not. Even when I
asked to be referred he wouldn’t know where to refer me to.”
treatment approaches that would also target this important aspect
(for a patient’s experience, see Box 8).
Non-motor Symptom Questionnaire
The high prevalence of NMS and the impact on the patients’ well-
being demands a more structural screening toward NMS during
the regular outpatient visits. For this purpose, a standardized,
validated NMS questionnaire specific for dystonia patients is
needed to identify the symptoms and to evaluate the effect
of treatment.
Recently, a novel 14-item self-completed questionnaire has
been introduced (110). This Dystonia Non-motor Symptoms
Questionnaire (DNMSQuest) covers seven domains including
sleep, autonomic functions, fatigue, emotional well-being,
stigma, activities of daily living, and sensory symptoms, and
was tested in craniocervical dystonia patients. It appeared robust
and easy to apply in daily practice, with just 14 questions that
could be answered in about 5min with yes or no. A possible
disadvantage is that it does not score the severity of symptoms,
for which additional information is required from the patient.
Furthermore, it has only been validated for CD, so further
validation in other dystonia subtypes is required. A European
network would facilitate larger studies to create a questionnaire
also for NMS severity and to validate the NMS questionnaire in
other dystonia subtypes ll.
Treatment of Non-motor Symptoms
Treatment of NMS is important not only to improve the
significant impact that they have on the quality of life
but also to investigate their effect on motor symptoms and
pathophysiological networks.
Psychiatric symptoms like depression and anxiety disorders
are associated with neurotransmitter disturbances and are
treated with medications influencing neurotransmitter systems
like serotonin, dopamine, and noradrenalin. Importantly, these
systems are involved in dystonia as well (111, 112). Safety profiles
of most medications are based on a healthy (or non-dystonia)
population and need further investigation in dystonia patients.
One study showed that prescribing selective serotonin reuptake
inhibitors (SSRIs) to CD patients is safe, with no deterioration of
motor symptoms, but the effect on non-motor symptoms needs
to be examined in larger studies investigating higher dose and
longer schedule (113).
Evidence regarding the best treatment for NMS such as
fatigue, sleep disturbances, and cognitive problems are still
at an even more rudimentary stage. Besides pharmacological
interventions, an approach including PT, cognitive therapy,
coping strategies, and caregiver support, possibly in the
context of a multidisciplinary rehabilitation program, could
possibly contribute to a better well-being and requires
further investigation.
An integrated treatment approach of motor and non-motor
symptoms aiming at improving quality of life requires further
research, also considering that the several dystonia forms have
their own pathopsychological mechanisms and related NMS
spectrum. Especially for the rare dystonia subtypes, this cannot
be realized without international collaboration.
Subjective Goals as Outcome Measures
In general, the goal of any treatment is to improve quality
of life and patient’s satisfaction. To date, the standard way of
assessing the effect of dystonia treatments is to measure the
reduction in motor symptoms and, more recently, non-motor
symptoms, which can be objectively measured. However, current
scales are often not fully capable of accurately reflecting changes
that are relevant for the patients. Indeed, small changes in
predefined scores can make a big difference in daily life in some
cases, while, on the other hand, measurable improvements do
not always translate in significant ameliorations in functioning
or independence.
A different approach could be to aim directly for functional
improvement in daily life, as defined by the patients themselves
(114, 115). One previous study examined the effectiveness of
GPi DBS in dystonia patients on preoperatively set of functional
priorities in daily living (116), measured with the Canadian
Occupational Performance Measure (COPM). Priorities varied
between patients but showed a significant improvement in
performance and satisfaction after DBS in all. Importantly,
improvement was reported both by the motor responders and by
several patients classified as non-responders based on the motor
outcome. Such an approach focuses on important improvements
for the individual patient that would not have been objectified
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BOX 8 | Patient’s experience.
Mother of 7-year-old girl with dystonia: “We were on a waiting list for a year and just recently we have started to go to regular psychologist meetings. I think it is so
important for family, friends and professionals to be aware and to be educated that dystonia doesn’t just affect people physically.”
with a general motor or non-motor symptom rating scale only
and could be applied also to other treatment such as BoNT,
psychotherapy or PT, or even to potential new treatments being
investigated in clinical trials (116, 117). A similar effect was also
shown in other studies, were patients’ perceptions in changes in
life after DBS were studied with thematic interviews, instead of
motor rating scales (118, 119).
A Multidisciplinary Approach
The diagnosis of dystonia motor symptoms, the recognition of
the non-motor spectrum, and the identification of syndromes are
very challenging. In addition, other factors can complicate the
diagnostic process, like an abnormal development in children and
the wide range of possible etiologies (120).
In other movement disorders, such as Parkinson’s disease,
a multidisciplinary approach has increasingly been shown to
be beneficial (121). Also in children with movement disorders
like dystonia, a multidisciplinary approach has already shown
significant improvement in phenotyping, a high diagnostic yield
and minimal diagnostic delay (120). Future research should
investigate the additional value of a multidisciplinary approach
also in the adult dystonia population.
The composition of a multidisciplinary team will vary at
different levels. All patients may benefit from experienced Allied
Health Professionals for support and specialized interventions
(102) and application of the principles of the International
Classification of Function (ICF). Children might require teams
with a pediatrician, geneticist, or a specialist in metabolic
diseases, although differences per center and per country can be
expected. Adults may benefit from a multidisciplinary approach
covering also the broad range of non-motor symptoms. A
European network could advise on the specialists that would
preferably be involved in the multidisciplinary team. When the
optimal composition is not possible in a single center, multicenter
collaboration can offer additional expertise. When highly
specialized professionals are needed, international collaboration
could be envisaged. In this way, multicenter collaborations could
help overcome the shortcomings of the single centers, possibly
also by implementing teleconsultation with external specialists.
For all dystonia patients, a dedicated multidisciplinary team
may shorten the diagnostic delay, improve the classification and
diagnostic yield, and play an important role in a timely and
optimal treatment. In addition, genetic counseling may decrease
the uncertainty for patients and families, not only concerning the
cause of their symptoms but also about the consequence for next
generations. Probably, this approach will result in reduced costs
by reducing unnecessary investigations and, with a timely correct
treatment, promoting faster participation in society.
Multicenter (international) collaborations pose several
challenges, starting from identifying the correct specialists,
allocating time, and solving technological communication issues
while preserving data safety. The reality of the different countries
with cultural and social differences, along with the geographical
and technical disparities, must also be taken into account.
PATIENT AND CAREGIVER PERSPECTIVE
As mentioned above, the route to dystonia diagnosis can
be very challenging, causing prolonged suffering for many
dystonia patients.
The impact of dystonia motor and non-motor symptoms
is also reflected in the patients’ stories Dystonia Europe
receives. The boxes within the text provide a short insight into
patients’ experiences.
Based on the evidence and reports collected, which reflect the
patients’ and caregivers perspective, there are some goals in the
care of dystonia patients that should be prioritized.
These include the following:
- Improving education and training for (young) neurologists
and for general practitioners to speed up diagnosis and
initiation of treatment;
- Promoting specialized dystonia centers across Europe with
expertise in diagnosing and treating patients with more severe
forms of the disease;
- Building up multidisciplinary teams, including, among others,
neurologists, physiotherapists, occupational therapists, and
psychologists for the care of dystonia patients;
- Training of physiotherapists and occupational therapists
specialized in the treatment of dystonia patients and
facilitating access to physiotherapy across Europe;
- Increasing awareness by developing standardized
dystonia information material translated to the different
European languages.
There are still major gaps in public understanding of dystonia
and the psychological and financial burden that it may bring,
in medical knowledge, and in timing of diagnosis and access
to treatment for dystonia patients across Europe. To close
these gaps and uniformly improve care and quality of life
for dystonia patients, we need to work together: the medical
profession, researchers, policy makers, patients, and carers.
Therefore, the establishment of a strong international European
dystonia network is much advocated by the dystonia community.
The opportunity to collaborate across borders on education
(with specialized dystonia training schools), research projects,
improvement of dystonia awareness, etc. is the base to achieve
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the best care and improve quality of life for dystonia patients
throughout Europe.
CONCLUSIONS
Although dystonia is the thirdmost commonmovement disorder
after tremor and Parkinson’s disease, it is still relatively rare.
The wide heterogeneity of dystonia presentations makes it
difficult to collect large numbers of specific dystonia subtypes
for research purposes. Previous studies tended to lump patients
with different forms of dystonia together (whether these were
about diagnosis, pathophysiology, or treatment), while there
are multiple different pathophysiological processes leading to
different dystonia phenotypes. This may have affected the results.
DystoniaNet Europe is born with the aim of connecting
dystonia experts and patients all over Europe in a network
that can form the basis for leveling care at an upper level
and for supporting large multicenter research project
to advance knowledge. Such a network could also lay
the foundations for a European registry to support
future dystonia studies by the collection of data from
different countries.
Leveraging existing infrastructure, we will be collaborating
and interconnecting with the ERN-RND; however, we will also
reach out to other networks such as the American Dystonia
Coalition, aiming at a continuous fruitful interchange, which
can enrich both associations and further advance knowledge
through collaboration.
With joined forces, dystonia research can reach an important
next level to further improve dystonia care and treatment.
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